Radiopharmaceutical Theranostics Market: Introduction
According to the report, the global radiopharmaceutical theranostics market was valued at US$ 0.84 Bn in 2020 and is projected to expand at a CAGR of 11% from 2021 to 2031. Nuclear medicine imaging is primarily based on the principle of using radioactive isotopes attached to specific molecules (i.e., radiopharmaceutical agents or radiotracers) to examine key biologic processes, including disease pathophysiology. Radiopharmaceuticals are agents used for both diagnostic and therapeutic purposes. Organizations across the world classify these differently. According to the WHO, these are categorized into ready-for-use radioactive goods, radionuclide generators, non-radioactive components (“kits”) for the production of labelled compounds containing a radioactive component, and precursors used for radiolabelling other substances prior to administration.
Request A Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=82604
The radiopharmaceutical market is projected to be driven by factors such as increase in therapeutic applications, public awareness, usage of hybrid imaging, technological advancements, efficient diagnosis & treatments, emergence of new radioisotopes, and replacement of traditional equipment.
Rise in Prevalence of Cancer to Drive Global Market
The significance of customized medicine has been growing rapidly, owing to a more urgent need to avoid unnecessary and expensive treatments. In radiopharmaceuticals, the theranostics approach is an established tool for specific molecular targeting, both for diagnostics and therapy. The visualization of potential targets could help predict if a patient would benefit from a particular treatment. According to the International Agency for Research on Cancer, the global cancer burden surged to 19.3 million cases and 10 million cancer deaths in 2020. By 2040, the number of new cancer cases per year is anticipated to reach 29.5 million, with 16.4 million cancer-related deaths.
Radiopharmaceutical theranostics is becoming an increasingly essential component of cancer treatment. Radioiodine is the classic radiotheranostic agent for clinical treatment of thyroid tumors. Radiolabeled metaiodobenzylguanidine is another prominent radiotheranostic drug, which has been used for diagnostic imaging and therapy of neuroblastoma, paraganglioma, and pheochromocytoma patients.
Request Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82604
Significant and promising advancements have been made in radiotheranostics for neuroendocrine tumors, prostate cancer, and other conditions. Few instance of radiopharmaceutical theranostics pair are 177Lu/68Ga, 111In, 223Ra/99Tc, 18NaF, 131I/123I, 124I, etc.
Radiopharmaceutical theranostics is gaining traction and will most likely be able to expand its scope to include new cancer biomarkers and indications in future. Hence, rise in the prevalence of cancer is projected to propel the demand for radiopharmaceutical theranostics over the next few years.
Lutetium (Lu) 177 to Dominate Global Market
In terms of radioisotope, the global radiopharmaceutical theranostics market has been classified into technetium-99, gallium-68, iodine-131, iodine-123, fluorine-18, yttrium-90, lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. The lutetium (Lu) 177 segment dominated the global radiopharmaceutical theranostics market in 2020 and the trend is anticipated to continue during the forecast period. The favorable nuclear characteristics as well as easy availability of high activity levels of high specific activity 177Lu are the major factors for the widespread interest in the clinical use of this radionuclide.
Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=82604
Oncology to Offer Lucrative Opportunities
Based on application, the global radiopharmaceutical theranostics market has been categorized into oncology, cardiology, and others. The oncology segment dominated the global radiopharmaceutical theranostics market in 2020. Most of the radioisotopes are used in oncology for diagnosis or radiation therapy. 68 Ga DOTATE and 177 Lu DOTATOC is the commonly used theranostics pair in diagnosis and treatment of neuroendocrine tumors.
High Number of Cyclotrons Facilities to Drive Global Market
In terms of source, the global radiopharmaceutical theranostics market has been bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment dominated the market in 2020. The segment is expected to expand at the highest CAGR from 2021 to 2031. The segment is likely to witness rapid growth, owing to a large number of existing cyclotron facilities across the world.
Targeted Therapeutic (Rx) to be Promising Segment
Based on approach, the global radiopharmaceutical theranostics market has been classified into targeted therapeutic (Rx) and companion diagnostic (DX). The targeted therapeutic (Rx) segment dominated the market in 2020. The segment is projected to expand at the highest CAGR from 2021 to 2031. Increasing evidence supports the efficacy and safety of targeted therapeutics, as well as an increase in overall survival.
Hospitals to be Major End Users
In terms of end user, the global radiopharmaceutical theranostics market has been divided into academic & research institutes, hospitals, and others. The hospitals segment dominated the market in 2020. The segment is anticipated to expand at the highest CAGR from 2021 to 2031. Rise in number of hospital facilities and favorable outcomes of treatment in hospitals due to the availability of a range of treatment options lead to high preference to hospitals.
Request for covid19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=82604
North America to Lead Radiopharmaceutical Theranostics Market
The global radiopharmaceutical theranostics market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2020, followed by Europe. North America accounted for a major share of the global radiopharmaceutical theranostics market in 2020. The high prevalence of neuroendocrine tumors (NETs) drives the radiopharmaceutical theranostics market in North America. Over 12,000 people in the U.S. are diagnosed with neuroendocrine tumors each year. The sensitivity and specificity of Ga-68 and Lu-177 as a theranostics pair have been evaluated in a number of clinical trials. This factor is expected to fuel the growth of the market in the region.
Competition Landscape
- The global radiopharmaceutical theranostics market is fragmented due to the presence of a large number of leading players. Key players operating in the global market include Nihon Medi-Physics, ITM Isotopen Technologien München AG, Advanced Accelerator Applications, Telix Pharmaceuticals, GE Healthcare, Theragnostics Ltd, NuView Life Sciences, Jubilant Pharma Limited, Lantheus Holdings, Inc., Curium Pharma, Bayer AG, and Clarity Pharmaceuticals. New product development through robust R&D
More Trending Reports by Transparency Market Research:
The report covers an overview of the industry along with a detailed explanation that provides a lot of insight.
The report also analyzes the production as well as management technology in various end-user industries.
An in-depth study in some new and prominent industry trends, analysis of the competition and regional analysis that is very detailed have been included in the report of the Radiopharmaceutical market for the review period of 2020 – 2027.There are many different factors that have caused the quick expansion of the Radiopharmaceutical market.
In addition to the above, government initiatives, as well as the competitive landscape that exists in the Radiopharmaceutical market through the forecast period, has been analyzed.Ask for report free sample with complete TOC and list of tables/figures @ https://www.datalibraryresearch.com/sample-request/radiopharmaceutical-market-2183Global Radiopharmaceutical Market Key Companies:Cardinal HealthGE HealthcareCuriumLantheus Medical ImagingBayer AGBracco ImagingEczacýbaþý-Monrol Nuclear ProductsNordionAdvanced Accelerator ApplicationsNTP RadioisotopesThe base year of the study is 2020 and the forecast period stretches all the way till 2027.
This has led to the creation of a strong understanding of the market for the upcoming years.
In addition to this, different latent growth factors, opportunities and restraints are evaluated for this advanced study and suggestions are made for the market that pertains to the forecast period.SegmentationThe Radiopharmaceutical market covers different regions such as North America, Latin America, Asia Pacific, Europe, and the Middle East & Africa.
Radiopharmaceutical Market: IntroductionAccording to the report, the global radiopharmaceutical market was valued at US$ 3.6 Bn in 2018 and is projected to expand at a CAGR of ~4% from 2019 to 2027.
Some of the factors driving the radiopharmaceutical market are expansion activities of key radiopharma players; applications in clinical trials; and increase in aging population, pipeline assessment of new drugs, and disease indication mortality.
Additionally, cost advantage over outsourced radioactive tracers and accessibility of technologically advanced diagnostic devices such as positron emission tomography scan (PET/CT) and a single-photon emission computerized tomography (SPECT) are playing a crucial role in propelling the radiopharmaceutical market.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=213Based on end user, the hospital segments accounted for major share of the global radiopharmaceutical market in terms of revenue in 2018.
Hospitals are major end-users of radiopharmaceutical products, which are used in the treatment of diseases such as cancer, cardiovascular heart diseases, neurological disorders, and diabetes.
According to government healthcare facilities, hospitals have reimbursement plans and advanced technology systems for disease treatment.Radiopharmaceutical products are made of radioactive agents, which are required to be handled by experts for treating cancer and other diseases.
Introduction of a new accelerator system for production of radioisotopes in Japan and Australia is projected to propel the radiopharmaceutical market.Some of the factors likely to boost the radiopharmaceutical market in Asia Pacific are increase in access to healthcare services; growth in per capita income; rise in demand for radiopharmaceuticals; surge in incidence of cancer and heart-related diseases; and speedy introduction of advanced technological systems such as PET/CT, SPECT, and a few accelerator systems.Buy Radiopharmaceutical Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=213=SRadiopharmaceutical Market: Key PlayersKey players are expanding their footprint to strengthen their positions in the global radiopharmaceutical market.
TheBusinessResearchCompany published its Coffee And Tea Manufacturing Global Market Report 2019 which provides strategists, marketers and senior management with the critical information they need to assess the global coffee and tea manufacturing market.
The report covers the coffee and tea manufacturing market’s segments- coffee and tea.Explore Complete Report https://www.thebusinessresearchcompany.com/report/coffee-and-tea-manufacturing-global-market-reportCoffee And Tea Manufacturing Global Market Report 2019 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 50+ geographies.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country.
It covers all the regions, key developed countries and major emerging markets.
The major regions included in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.Request to get the sample of this report https://www.thebusinessresearchcompany.com/sample.aspx?id=2031=smpMajor companies are introducing fortified beverages such as functional juices, functional water with health benefits such as water balance, weight management and improved digestion as the major trends witnessed in the global coffee and tea manufacturing market.
With busy lifestyles, influence of social media on the market, impact of new cuisines on the market, and low cost foods, the scope and potential for the global coffee and tea manufacturing market is expected to significantly rise in the forecast period.Get Discount On This Report https://www.thebusinessresearchcompany.com/sample.aspx?id=2031=discountChapters from Table of Content:Chapter 1.
